- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05543798
VT Ablation in the iCMR (VISABL-VT)
September 18, 2022 updated by: Imricor Medical Systems
Vision-MR Ablation Catheter 2.0 for the Treatment of Ventricular Tachycardia
The VISABL-VT is a prospective, single-arm, multi-center, interventional investigation of the safety and efficacy of radiofrequency (RF) ablation of ventricular tachycardia associated with ischemic cardiomyopathy performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
64
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kate Lindborg, PhD
- Phone Number: 9528188400
- Email: kate.lindborg@imricor.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Documented (ECG/EGM) spontaneous episode of sustained ventricular tachycardia within 6 months
- Diagnosis of Ischemic Cardiomyopathy
- AAD therapy refractory, contraindicated, not tolerated, or not desired
- 18 years or older
Exclusion Criteria:
- Implanted with non-MR compatible medical devices or contraindicated for an MRI
- Presence of intracardiac thrombus (verified via CT/MRI/echocardiogram within 48 hours of procedure - or at start of procedure)
- Thrombocytopenia or coagulopathy
- Mechanical mitral and/or aortic valve precluding access to the left ventricle
- Severe aortic stenosis
- Myocardial infarction requiring stent implantation within 90 days of procedure
- Previous cardiac surgery within 60 days of procedures
- Class IV Heart Failure
- Ejection Fraction (EF) < 25%
- Patients with a glomerular filtration rate (GFR) < 30
- Women who are pregnant
- Life expectancy < 12 months
- Enrollment in another study without sponsor approval
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Non-Randomized
All subjects with ventricular tachycardia associated with ischemic cardiomyopathy will undergo catheter ablation using the Vision-MR Ablation Catheter 2.0
|
Catheter ablation of ventricular tachycardia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Efficacy Endpoint
Time Frame: 30 minutes post procedure
|
Acute success defined as absence of inducible clinical ventricular tachycardia (VT) following the last RF application with with the investigational device.
|
30 minutes post procedure
|
Primary Safety Endpoint
Time Frame: 7 days
|
Composite of any procedure or device related serious adverse events through 7 days post index ablation procedure
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Efficacy Endpoint
Time Frame: 6 months
|
Chronic success defined as 6-month freedom from recurrence of sustained VT or VT requiring intervention and freedom from new or increased dose of Class I or III antiarrhythmic drugs (AAD) at 6 months following the index ablation procedure.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
December 1, 2022
Primary Completion (Anticipated)
June 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
September 14, 2022
First Submitted That Met QC Criteria
September 14, 2022
First Posted (Actual)
September 16, 2022
Study Record Updates
Last Update Posted (Actual)
September 21, 2022
Last Update Submitted That Met QC Criteria
September 18, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VISABL-VT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventricular Tachycardia
-
University of PretoriaCompletedSupra-ventricular TachycardiaSouth Africa
-
Ottawa Heart Institute Research CorporationNot yet recruitingVentricular Fibrillation | Ventricular Tachycardia | Ventricular Arrhythmias | Recurrent Ventricular Tachycardia
-
Armgo Pharma, Inc.Food and Drug Administration (FDA)RecruitingCatecholaminergic Polymorphic Ventricular Tachycardia Type 1United States, Netherlands
-
University of Turin, ItalyAzienda Unità Sanitaria Locale Reggio Emilia; IRCCS Sacro Cuore Don Calabria... and other collaboratorsRecruitingRefractory Ventricular TachycardiaItaly
-
Thermedical, Inc.Not yet recruitingRefractory Ventricular TachycardiaUnited States, Canada
-
John SappCompleted
-
University of California, Los AngelesCompletedRefractory Ventricular TachycardiaUnited States
-
Hospital General Universitario Gregorio MarañonCompletedMonomorphic Ventricular TachycardiaSpain
-
Abbott Medical DevicesTerminatedMonomorphic Ventricular TachycardiaUnited States, United Kingdom, France, Australia, Italy
-
Abbott Medical DevicesWithdrawn
Clinical Trials on Vision-MR Ablation Catheter 2.0
-
University of LeipzigPhilips Healthcare; Heart Center Leipzig - University Hospital; Imricor Medical...TerminatedAtrial FlutterGermany
-
University of LeipzigPhilips Healthcare; Heart Center Leipzig - University Hospital; Imricor Medical...TerminatedAtrial FlutterGermany
-
Charles University, Czech RepublicRecruitingAtrial FibrillationCzechia
-
Sheba Medical CenterMedtronicUnknownPremature Ventricular Contraction
-
Oxford University Hospitals NHS TrustRoyal Bournemouth and Christchurch Hospitals NHS Foundation TrustCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompletedAtrial Fibrillation | Paroxysmal Atrial FibrillationUnited States, France, Italy, Canada, Czechia
-
Cedars-Sinai Medical CenterBiosense Webster, Inc.Recruiting
-
Emory UniversityBoston Scientific CorporationCompleted
-
The Cleveland ClinicAtriCure, Inc.Not yet recruitingHeart Failure | Atrial FibrillationUnited States
-
Medtronic Bakken Research CenterTerminatedAtrial FibrillationNetherlands